Skip to main content
In stock | Targeted Therapy

Carfilzomib

Oncology Type Hematologic (Multiple Myeloma)
Drug Class / Mechanism Proteasome Inhibitor
No Image
Description

Carfilzomib is classified as a Proteasome Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Hematologic (Multiple Myeloma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3